Sanofi · SNY · FY2026 Q3 · Calendar Q4 2026
Sanofi lifts 2026 outlook as Dupixent and launches drive Q3 growth
Sanofi’s Q3 analysis supports the view that sustained Dupixent demand and newer launches are underpinning growth: management reported 14% sales growth and raised 2026 guidance. The durability of that trajectory remains contingent on managing Dupixent’s coming loss of exclusivity, pricing and gross-to-net pressures, and pipeline execution.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about SNY FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management raised 2026 guidance to 13–15% sales growth and 15–17% EPS growth. Sanofi also announced four new immunology compounds in its expanded Regeneron alliance while discontinuing two late-stage assets, and described plans to embed AI across R&D and increase China-based innovation activity.
Guidance delta
Raised 2026 guidance to 13–15% sales growth and 15–17% EPS growth, according to the Q3 call analysis; the prior-quarter analysis cited approximately 10% full-year sales growth.
Key takeaways
- Q3 sales rose 14% year over year to €14.4 billion, with Dupixent exceeding €5 billion in quarterly revenue.
- Management attributed growth to Dupixent and launches including ALTUVIIIO, Ayvakit and Rezurock.
- The expanded Regeneron collaboration adds four immunology compounds; the company also plans broader AI use in R&D and increased China innovation activity.
Management priorities
- Sustain growth from Dupixent and recent launches while preparing for Dupixent’s loss of exclusivity.
- Advance and prioritize the pipeline, including the expanded Regeneron collaboration and planned clinical milestones.
- Apply AI across R&D and increase China-based innovation activity; pursue disciplined business development.
Follow SNY with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationSanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases.…
Historical context
All SNY earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| IDXX IDEXX Laboratories, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +19.5% | IDEXX raises 2026 outlook as diagnostics, placements and software support growth |
| AXSM Axsome Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -14.0% | Axsome reports Q3 growth led by AUVELITY; pipeline advances |
| TEM Tempus AI, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +9.5% | Tempus pairs Q3 growth with new partnerships and execution risks |
| AZN AstraZeneca PLC | FY2026 Q3 · Calendar Q4 2026 | +7.3% | +7.0% | AstraZeneca pairs solid growth with pipeline investment and restructuring |
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
Latest beats and misses
Who reports nextBeat on EPS
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the SNY recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-02T16:05:31.985414+00:00
- FN2 earnings calendar · 2026-11-02T01:23:13.261602+00:00
- Polygon adjusted daily market bars · 2026-11-02T16:40:44.025567+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-02T16:40:44.021574+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-02. For educational purposes only; not investment advice.